Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Net Income (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Net Income for 17 consecutive years, with -$7.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 81.46% to -$7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$365.9 million, a 187.21% decrease, with the full-year FY2025 number at -$365.9 million, down 187.43% from a year prior.
  • Net Income was -$7.9 million for Q4 2025 at Myriad Genetics, up from -$27.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $24.6 million in Q3 2021 to a low of -$330.5 million in Q2 2025.
  • A 5-year average of -$44.8 million and a median of -$29.3 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: soared 261.84% in 2021, then crashed 800.54% in 2025.
  • Myriad Genetics' Net Income stood at -$7.6 million in 2021, then tumbled by 456.58% to -$42.3 million in 2022, then grew by 26.24% to -$31.2 million in 2023, then tumbled by 36.54% to -$42.6 million in 2024, then skyrocketed by 81.46% to -$7.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Net Income are -$7.9 million (Q4 2025), -$27.4 million (Q3 2025), and -$330.5 million (Q2 2025).